Dual inhibition of tumor energy pathway by 2-deoxyglucose and metformin is effective against a broad spectrum of preclinical cancer models

Jae Ho Cheong, Eun Sung Park, Jiyong Liang, Jennifer B. Dennison, Dimitra Tsavachidou, Catherine Nguyen-Charles, Kwai Wa Cheng, Hassan Hall, Dong Zhang, Yiling Lu, Murali Ravoori, Vikas Kundra, Jaffer Ajani, Ju Seog Lee, Waun Ki Hong, Gordon B. Mills

Research output: Contribution to journalArticle

156 Scopus citations

Abstract

Tumor cell proliferation requires both growth signals and sufficient cellular bioenergetics. The AMP-activated protein kinase (AMPK) pathway seems dominant over the oncogenic signaling pathway suppressing cell proliferation. This study investigated the preclinical efficacy of targeting the tumor bioenergetic pathway using a glycolysis inhibitor 2-deoxyglucose (2DG) and AMPK agonists, AICAR and metformin. We evaluated the in vitro antitumor activity of 2DG, metformin or AICAR alone, and 2DG in combination either with metformin or AICAR. We examined in vivo efficacy using xenograft mouse models. 2DG alone was not sufficient to promote tumor cell death, reflecting the limited efficacy showed in clinical trials.Acombined use of 2DG and AICAR also failed to induce cell death. However, 2DG and metformin led to significant cell death associated with decrease in cellular ATP, prolonged activation of AMPK, and sustained autophagy. Gene expression analysis and functional assays revealed that the selective AMPK agonist AICAR augments mitochondrial energy transduction (OXPHOS) whereas metformin compromises OXPHOS. Importantly, forced energy restoration with methyl pyruvate reversed the cell death induced by 2DG and metformin, suggesting a critical role of energetic deprivation in the underlying mechanism of cell death. The combination of2DGand metformin inhibited tumor growth in mouse xenograft models. Deprivation of tumor bioenergetics by dual inhibition of energy pathways might be an effective novel therapeutic approach for a broad spectrum of human tumors.

Original languageEnglish (US)
Pages (from-to)2350-2362
Number of pages13
JournalMolecular cancer therapeutics
Volume10
Issue number12
DOIs
StatePublished - Dec 1 2011

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Dual inhibition of tumor energy pathway by 2-deoxyglucose and metformin is effective against a broad spectrum of preclinical cancer models'. Together they form a unique fingerprint.

  • Cite this

    Cheong, J. H., Park, E. S., Liang, J., Dennison, J. B., Tsavachidou, D., Nguyen-Charles, C., Cheng, K. W., Hall, H., Zhang, D., Lu, Y., Ravoori, M., Kundra, V., Ajani, J., Lee, J. S., Hong, W. K., & Mills, G. B. (2011). Dual inhibition of tumor energy pathway by 2-deoxyglucose and metformin is effective against a broad spectrum of preclinical cancer models. Molecular cancer therapeutics, 10(12), 2350-2362. https://doi.org/10.1158/1535-7163.MCT-11-0497